Supply update: Fluarix Tetra and Fluarix

GSK advises supply of new quadrivalent (four-strain) influenza vaccine, Fluarix® Tetra, recently launched in Australia and available for private sale, is no longer available for the remainder of the 2015 influenza season due to high levels of demand.

Fluarix Tetra is an influenza vaccine indicated for the active immunisation of adults and children from 3 years of age for the prevention of influenza disease caused by the influenza virus types A and B contained in the vaccine.1 

Private market supply of Fluarix®, GSK’s trivalent (three strain) influenza vaccine, is also no longer available for the remainder of 2015 on the private market. 

Supply of Fluarix to the National Immunisation Program (NIP) and state-based vaccination programs is not affected. 

Reference 
1. Fluarix Tetra product information


For more information, please contact GSK medical information on 1800 033 109. 


For media enquiries, please contact: 
Kim O’Donohue 
Communications Manager, Pharmaceuticals 
kim.j.odonohue@gsk.com 
0477 322 431